Alembic Pharma Wins USFDA Approval for Heart Disease Drug
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg.
The company announced the approval, marking a significant development in the pharmaceutical field.
No additional statement from the company is provided.
Ruchika Sharma, Correspondent for the Business Section at Medical Dialogue, reported on the update.
- Alembic Pharmaceuticals Limited received USFDA approval for Ticagrelor Tablets.
- Ruchika Sharma covers pharmaceutical field updates, policy, and healthcare news.
Alembic Pharma's approval is a notable event in the healthcare industry.
Author's summary: Alembic Pharma received USFDA approval for a heart disease drug.
More News
- Why busy educators need AI with guardrails
- Dettwiler's horrific Sepang accident: Bring back Moto2 and Moto3 warm-ups
- South Korea is up in arms – and that’s a good thing for European defences - Monocle
- Prescribed Burns To Begin In Forest - myMotherLode.com
- Granules India gets USFDA EIR for Bonthapally facility